Document Detail

Does the expression of fascin-1 and tumor subclassification help to assess the risk of recurrence and progression in t1 urothelial urinary bladder carcinoma?
MedLine Citation:
PMID:  18587253     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: To evaluate the prognostic value of T1 subclassification and fascin-1 expression in T1 human urothelial cell carcinoma of the bladder. MATERIALS AND METHODS: In a prospective study with 105 consecutive patients, T1 tumors were subclassified into 2 groups according to the depth of tumor invasion. The tunica muscularis mucosae was used as a landmark. The expression of fascin-1 was examined by using an anti-fascin-1 mouse monoclonal antibody and was evaluated semiquantitatively for both intensity and distribution. The patients were followed up for 27.3 +/- 13.7 months. RESULTS: The T1 tumor subclassification was feasible in 99 patients (94%). T1a tumor was detected in 77 patients (73%), T1b tumor in 22 patients (21%). An invasive tumor was found in 5 patients (4.8%) during the restaging transurethral resection of the bladder. The risk of understaging in patients with T1b tumor was 18%. There was not a significant difference in time to the recurrence in the T1a and the T1b group. The progression-free survival rates were significantly different between both groups (p = 0.0034). No correlation was found between fascin-1 positivity and the depth of tumor invasion. Fascin-1 positivity did not correlate with recurrence or the progression-free intervals. In the multivariate analysis, only the extent of lamina propria invasion was an independent predictor of the tumor progression. The fascin positivity was not an independent prognostic factor relating to the risk of recurrence or progression. CONCLUSION: The finding of T1b tumor was connected with a significantly higher risk of progression and understaging. The fascin-1 expression did not correlate with the depth of tumor invasion or with the tumor recurrence or progression.
V Soukup; M Babjuk; J Dusková; M Pesl; M Szakáczová; L Zámecník; J Dvorácek
Related Documents :
8326553 - Technique of mitomycin c instillation in the treatment of upper urinary tract urothelia...
1636233 - Recurrent or aggressive bladder cancer. indications for adjuvant intravesical therapy.
18056463 - The novel combination of chlorpromazine and pentamidine exerts synergistic antiprolifer...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-06-27
Journal Detail:
Title:  Urologia internationalis     Volume:  80     ISSN:  1423-0399     ISO Abbreviation:  Urol. Int.     Publication Date:  2008  
Date Detail:
Created Date:  2008-06-30     Completed Date:  2008-07-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0417373     Medline TA:  Urol Int     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  413-8     Citation Subset:  IM    
Copyright Information:
2008 S. Karger AG, Basel.
Department of Urology, General Teaching Hospital, 1st Medical Faculty, Charles University, Prague, Czech Republic.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Carcinoma, Transitional Cell / genetics,  metabolism,  mortality,  pathology*
Carrier Proteins / genetics*,  metabolism
Confidence Intervals
Gene Expression Regulation, Neoplastic
Microfilament Proteins / genetics*,  metabolism
Middle Aged
Neoplasm Invasiveness / genetics,  pathology*
Neoplasm Recurrence, Local / genetics*,  mortality
Neoplasm Staging
Odds Ratio
Proportional Hazards Models
Prospective Studies
Risk Assessment
Survival Analysis
Tumor Markers, Biological / analysis*,  genetics
Urinary Bladder Neoplasms / genetics,  metabolism,  mortality,  pathology*
Reg. No./Substance:
0/Carrier Proteins; 0/Microfilament Proteins; 0/Tumor Markers, Biological; 146808-54-0/fascin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arsenic methylation capability, heme oxygenase-1 and NADPH quinone oxidoreductase-1 genetic polymorp...
Next Document:  Prevalence of prostate cancer in end-stage renal disease patients.